Abstract 92P
Background
Nutrition and immune status are two important factors that affect the occurrence and prognosis of tumors. Evaluating the nutritional and immune status of patients before treatment plays an important role in guiding the development of treatment plans and predicting treatment tolerance. In view of this, this study investigated the nutritional and immune status (BMI, PNI, and lymphocyte subset (NKTB) typing and absolute count) of nasopharyngeal carcinoma patients before treatment, and compared them with the nutritional and immune status of healthy individuals undergoing physical examinations, hoping to provide reference for the assessment of nutritional and immune status of nasopharyngeal carcinoma patients before treatment.
Methods
The study investigated the pretreatment nutritional and immune status (BMI, PNI, and percentage and absolute count of lymphocyte subpopulation) of 201 Newly diagnosed NPC cases and 332 age-sex-matched healthy controls.
Results
PNI was lower in patients with NPC than in healthy controls in both sexes and at different age groups (P < 0.001). Healthy controls had higher BMI than those with NPC (P < 0.005), but there was no difference across the age subgroups. In the NPC group, the absolute numbers of LYM, ALB, and TBNK (CD3+, CD3+CD4+, CD3+ CD8 +, CD16+CD56+, and CD19+) cell subsets were lower than those in the healthy control group (P < 0.001). A comparison of lymphocyte subpopulations in nasopharyngeal carcinomas at different stages revealed that CD3+CD8+(%) in N3 patients was higher than in N0-2. Patients who acquired metastases had higher CD19+ (%). The multifactorial combination index for the differential diagnosis of NPC, which included PNI, EBV, and immunological status, had a sensitivity of 81.59% and specificity of 96.08%.
Conclusions
The nutritional and immune statuses of NPC patients were reduced prior to treatment, and the evaluation of nutritional and immune statuses prior to treatment of patients with NPC at the time of diagnosis is of guiding significance for subsequent anti-tumor treatment, which is worth promoting and applying in the clinic.
Legal entity responsible for the study
The authors.
Funding
Sichuan Science and Technology Program (2023NSFSC1446).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
63P - Single-cell RNA-seq combined with bulk RNA-seq revealed the involvement of pancreatic cancer tissue-resident macrophages in tumour progression and the immunotherapy response
Presenter: Bin Wu
Session: Poster Display session
Resources:
Abstract
64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model
Presenter: Rui Coelho
Session: Poster Display session
Resources:
Abstract
68P - Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Presenter: Ainara Soria Rivas
Session: Poster Display session
Resources:
Abstract
69P - Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
Presenter: elena speziale
Session: Poster Display session
Resources:
Abstract
70P - Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
71P - Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Presenter: Konstantinos Lallas
Session: Poster Display session
Resources:
Abstract
72P - Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Presenter: Tristan Lim
Session: Poster Display session
Resources:
Abstract
73P - Impact of Assessment-to-Treatment Interval on the Predictive Value of PD-L1 Expression in Melanoma
Presenter: Cecilie Vestergaard
Session: Poster Display session
Resources:
Abstract
74P - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients
Presenter: Marie Weitemeyer
Session: Poster Display session
Resources:
Abstract
75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer
Presenter: Yong Song
Session: Poster Display session
Resources:
Abstract